Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Pulmonary Complications Clear all
Withdrawn Phase 3 Interventional

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

NCT04361552
View directory record Official record
Conditions
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions
Best Practice, Tocilizumab
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 5, 2026, 7:41 PM EDT
Completed No phase listed Observational Results available

Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic

NCT04385238
View directory record Official record
Conditions
COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety, Depression, Ptsd, Coronavirus
Interventions
This is an online survey with no intervention.
Other
Lead sponsor
Pregistry
Industry
Eligibility
18 Years and older · Female only
Enrollment
6,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

NCT04372589
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

NCT04374565
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
Interventions
High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

NCT04771611
View directory record Official record
Conditions
Covid19, Coronavirus Infection
Interventions
Fisetin, Placebo
Drug
Lead sponsor
James L. Kirkland, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 5, 2026, 7:41 PM EDT
Completed No phase listed Observational

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

NCT04706533
View directory record Official record
Conditions
Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
Interventions
Biomarkers of inflammation
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3,402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 5, 2026, 7:41 PM EDT
Completed No phase listed Observational

COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications

NCT04535128
View directory record Official record
Conditions
Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism, Myocardial Infarction, Stroke
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
11,000 participants
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 5, 2026, 7:41 PM EDT
Completed No phase listed Observational

Impact of COVID-19 on Surgical Outcomes

NCT06197282
View directory record Official record
Conditions
COVID-19, Surgical Outcomes, Postoperative Complications
Interventions
Major surgery involving general anesthesia
Procedure
Lead sponsor
Kern Medical Center
Other
Eligibility
Not listed
Enrollment
7,696 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 5, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 5, 2026, 7:41 PM EDT
Completed No phase listed Observational

Maternal Morbidity and Mortality During the COVID-19 Pandemic

NCT04519502
View directory record Official record
Conditions
COVID-19, Pregnancy Complications
Interventions
Not listed
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
25,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Phase 2a MIB-626 vs. Placebo COVID-19

NCT05038488
View directory record Official record
Conditions
Covid19, Stage 1 Acute Kidney Injury
Interventions
MIB-626, Placebo, Home Treatment
Drug · Other
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 5, 2026, 7:41 PM EDT
Withdrawn Phase 1 Interventional

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

NCT05286255
View directory record Official record
Conditions
COVID-19 Pneumonia, Viral Pneumonia
Interventions
Allogeneic Mesenchymal Stromal Cells
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 5, 2026, 7:41 PM EDT
Not listed No phase listed Observational

Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection

NCT04491227
View directory record Official record
Conditions
Covid19, AKI, CKD, ESRD, Transplant;Failure,Kidney
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19

NCT04718220
View directory record Official record
Conditions
Covid19, Pregnancy Related, Maternal Complication of Pregnancy, Coronavirus, Neonatal Infection, Prenatal Stress, Preterm Birth
Interventions
Antibody testing for SARS-CoV-2 IgG, Testing for SARS-CoV-2 RNA, Testing for SARS-CoV-2 IgM/IgG
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 5, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

NCT04360551
View directory record Official record
Conditions
COVID-19
Interventions
Telmisartan 40mg, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

NCT04373460
View directory record Official record
Conditions
SARS-CoV 2
Interventions
SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
29
States / cities
Birmingham, Alabama • Chinle, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 5, 2026, 7:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pilot Study for PET/MR Imaging of Covid-19

NCT04954248
View directory record Official record
Conditions
Brain Diseases, Covid19
Interventions
Injected radiotracer with PET Insert
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 5, 2026, 7:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Baby2Home (B2H) Mobile Health Application

NCT05595486
View directory record Official record
Conditions
COVID-19 Pandemic, Health Knowledge, Attitudes, Practice, Perinatal Depression, Mental Health Wellness, Post Partum Depression
Interventions
Baby2Home Mobile Application
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

NCT04909853
View directory record Official record
Conditions
Renal Impairment
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 5, 2026, 7:41 PM EDT
Completed No phase listed Observational

Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol

NCT05384899
View directory record Official record
Conditions
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Covid19, Sars-CoV-2 Infection
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 5, 2026, 7:41 PM EDT
Active, not recruiting No phase listed Observational

Impact of COVID-19 on GU Disease

NCT04761107
View directory record Official record
Conditions
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
15,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 5, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

NCT06586216
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 5, 2026, 7:41 PM EDT